Image:
Marek Poszepczynski and Ailsa Craig of International Biotechnology Trust
Crises are well-known for accelerating change, and the Covid-19 pandemic was no exception.
Had the delivery of vaccines and therapies not been urgently fast-tracked, countless more lives could have been lost. Conditional drug approvals were key to the rapid pandemic response, and their success...
To continue reading this article...
Join Investment week
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
